Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum on ulcerative colitis

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fakultas Kedokteran Universitas Indonesia

Criteria

Inclusion Criteria:

• age ≥18 years old

• ulcerative colitis patients who are treated by 5-aminosalicylic acid (5-ASA) 3x500 mg

• agreed to participate in this study

Exclusion Criteria:

• ulcerative colitis patients who are treated by corticosteroid, immunosuppressive agents and biologic agents

• allergic to Ganoderma lucidum

• could not be randomised and participate in this study by clinical judgement